2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.05 Repetto

PP01.05 Repetto - Abstract

Pdf Summary

The document discusses the landscape of MYC gene amplification in lung adenocarcinoma (LUAD) and its implications for targeted therapy. The study analyzed 5435 LUAD samples and found that 8% harbored MYC amplification, with varying segment sizes and total copy numbers. Some MYC amplifications were identified on extrachromosomal DNA (ecDNA). Common concurrent oncogenic alterations included EGFR, KRAS, and BRAF mutations. MYC amplifications were mutually exclusive with ROS1 fusions, MET mutations, and MYCL amplifications, while co-occurring with TP53 mutations and ERBB2 amplifications. Focal MYC amplifications were associated with drug resistance mutations like ALK and RET fusions. The findings suggest MYC amplifications are a significant driver in LUAD, with some cases lacking other actionable mutations and others linked to acquired resistance mechanisms. Overall, the study highlights the heterogeneity of genomic events driving MYC amplification in LUAD and the need for tailored treatment strategies.

Keywords

MYC gene amplification

lung adenocarcinoma

LUAD

targeted therapy

extrachromosomal DNA

oncogenic alterations

drug resistance mutations

genomic events

tailored treatment strategies

acquired resistance mechanisms